A Technique to Induce Chronic Experimental Autoimmune Dry Eye in Rats
JoVE Encyclopedia of Experiments
Immunology
0 views • 3:03 min • August 20th, 2025
Take a rat previously immunized with an antigen-adjuvant emulsion containing lacrimal gland-derived autoantigens and foreign antigens.
Re-inject the emulsion and intraperitoneally inject pertussis toxin, ensuring maximal T cell activation.
Activated cells differentiate into circulating effector memory T cells, TEMs and tissue-resident memory T cells, TRMs. A percentage of TRMs resides in ocular surface tissues.
After a defined interval, inject the antigens into the forniceal sub-conjunctiva and lacrimal glands, inducing localized inflammation.
Subconjunctival antigen-presenting cells, APCs, present antigens to the TRMs, triggering cytokine release.
Cytokines induce conjunctival epithelial cells to release chemokines, which recruit TEMs.
APCs reactivate the infiltrated TEMs, triggering proinflammatory cytokine release.
Cytokines cause the death of mucin-producing conjunctival goblet cells, decreasing mucin levels, and causing tear film instability.
Cytokines induce lacrimal gland cell death — reducing tear production — and stimulate corneal epithelial cells to produce matrix metalloproteinases, damaging the cornea.
Assess the rat for the clinical features indicating successful dry eye induction.
On day zero, distribute 200 microliters of the emulsion which contains 1 milligram of lacrimal gland extract and 200 micrograms of ovalbumin, and complete Freund's adjuvant into 1-milliliter Luer-lock syringes, and equip the syringes with 27-gauge needles.
Without using anesthesia, subcutaneously inject the emulsion at the base of the rat tails. Then, on day 14 in a similar manner, inject 200 microliters of the same antigen and incomplete Freund's Adjuvant. On the same day, intraperitoneally inject 300 nanograms of pertussis toxin in 100 microliters of PBS.
On day 48, weigh the required amount of ovalbumin and dissolve it in PBS, then, combine ovalbumin with the defrosted lacrimal gland extract prepared earlier in this video, making antigen solution containing 1 milligram per milliliter of ovalbumin and 1 milligram per milliliter of lacrimal gland extract.
After anesthetizing the rats, inject 5 microliters of antigen into the fornicial subconjuctiva of the eye, then, inject 20 microliters of antigen into the lacrimal gland.
Overview
This study investigates the induction of dry eye in rats through the administration of an antigen-adjuvant emulsion. The process involves T cell activation and the subsequent immune response leading to inflammation and tissue damage in the ocular surface.
Key Study Components
Area of Science
- Immunology
- Ophthalmology
- Neuroscience
Background
- Dry eye is a common condition characterized by inflammation and damage to the ocular surface.
- Understanding the immune mechanisms involved can help in developing targeted therapies.
- The role of T cells in ocular surface inflammation is crucial for studying dry eye pathophysiology.
- This model uses rat subjects to simulate human dry eye conditions.
Purpose of Study
- To establish a reliable animal model for studying dry eye disease.
- To investigate the immune response and cytokine release in the context of dry eye.
- To assess the impact of T cell activation on ocular surface health.
Methods Used
- Immunization of rats with an antigen-adjuvant emulsion.
- Intraperitoneal injection of pertussis toxin to activate T cells.
- Subconjunctival injection of antigens to induce localized inflammation.
- Assessment of clinical features indicating dry eye induction.
Main Results
- Successful activation of T cells leading to the differentiation into effector memory T cells and tissue-resident memory T cells.
- Induction of localized inflammation in ocular tissues following antigen presentation.
- Release of cytokines resulting in the death of mucin-producing goblet cells.
- Reduction in tear production and instability of the tear film.
Conclusions
- The study provides insights into the immune mechanisms underlying dry eye disease.
- The rat model effectively simulates the pathophysiology of dry eye in humans.
- Future research can build on these findings to explore therapeutic interventions.
Frequently Asked Questions
Executive Industry Relevance
This model enables mechanistic de-risking of T cell-mediated ocular surface pathology, supporting target validation in autoimmune dry eye therapeutics. By recapitulating effector and tissue-resident memory T cell dynamics, it provides a disease-relevant system for preclinical evaluation of immunomodulatory candidates. The approach enhances predictive confidence in lead identification by linking antigen-specific T cell activation to functional readouts of tear film instability and corneal damage.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses involving antigen-specific T cell activation in ocular autoimmunity.
- Operational Value: Clarifies pathogenic pathways through quantification of TEM and TRM differentiation in lymphoid and ocular tissues.
- Scientific Value: Supports biological de-risking by modeling cytokine-driven goblet cell loss and lacrimal gland dysfunction.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems with measurable inflammatory outputs for downstream compound screening.
- Operational Value: Enables assay standardization via reproducible antigen rechallenge protocols in ocular surface tissues.
- Scientific Value: Delivers quantitative dependent variable measurements such as mucin levels, tear production, and corneal integrity for hit-to-lead progression.
Translational & Preclinical Research
- Scientific Value: Aligns with human dry eye pathophysiology through increased effector memory T cells in eyeball tissue.
- Operational Value: Ensures translational continuity from discovery to preclinical validation via consistent immune readouts.
- Scientific Value: Facilitates risk-adjusted advancement decisions by linking immunological parameters to clinical features of dry eye.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, enabling iterative refinement of immunomodulatory candidates.
- Discovery Biology: Supports hypothesis testing of antigen-driven T cell responses and pathway clarification in ocular inflammation.
- Screening: Delivers assay readiness through standardized antigen solution preparation and ocular injection techniques.
- Analytics: Provides statistical outputs on cytokine release, cell death, and functional deficits to compare experimental conditions.
- Translational Research: Connects to preclinical continuity via disease-relevant system modeling of human dry eye immune mechanisms.
- Enterprise Reuse: Establishes a reusable platform for iterative target confirmation and biomarker qualification across immunomodulatory programs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through mechanistic insight into T cell-mediated tissue damage.
- Operational Value: Standardization and reproducibility via defined immunization and rechallenge intervals.
- Strategic Value: Better go/no-go decisions by reducing late-stage biological risk in ocular immunomodulation programs.
- Portfolio Impact: Risk-adjusted prioritization based on quantitative disease severity metrics.
Implementation Considerations
- Requires expertise in immunology, ocular tissue handling, and antigen preparation.
- Dependent on sterile injection techniques and controlled antigen-adjuvant formulation.
- Necessitates cross-team standardization for consistent T cell activation and ocular readouts.
- Involves adaptation considerations when translating rat ocular anatomy to other model systems.
- Practical limitations include variability in TRM homing efficiency and antigen-specific T cell frequency.
Biopharma FAQs
A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
Related Videos
0 Views
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Related Videos
0 Views
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Related Videos
0 Views
A Technique to Induce Chronic Experimental Autoimmune Dry Eye in Rats
Related Videos
0 Views
A Technique to Induce Chronic Experimental Autoimmune Dry Eye in Rats
Related Videos
0 Views
Performing Injection into Palpebral Portion of the Superior Lacrimal Gland: A Technique for Inducing Dry Eye Disease in Rabbit Model
Related Videos
0 Views
Performing Injection into Orbital Lobe of Superior Lacrimal Gland: A Technique for Inducing Dry Eye Disease in Rabbit Model
Related Videos
0 Views
Quantification of Tear Volume in an Autoimmune Dry Eye Rat Model using the Phenol Red Thread
Related Videos
0 Views
Assessment of Cornea and Tear Smoothness in an Autoimmune Dry Eye Rat Model
Related Videos
0 Views
Fluorescein Staining in an Autoimmune Dry Eye Rat Model to Examine Corneal Damage
Related Videos
0 Views
Last updated: 22 August 2026